Stock DRW8 DRÄGERWERK AG & CO. KGAA
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Drägerwerk AG & Co. KGaA Xetra

Equities

DRW8

DE0005550602

Market Closed - Xetra
Other stock markets
 09:05:20 01/07/2024 pm IST 		After market 09:22:04 pm
44.1 EUR -0.45% Intraday chart for Drägerwerk AG & Co. KGaA 44.15 +0.11%
20/06 Warburg Research raises target for Drägerwerk to 64 euros - 'Buy' DP
20/06 DRAEGERWERK : Warburg Research gives a Buy rating ZD

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • With a P/E ratio at 10.21 for the current year and 8.69 for next year, earnings multiples are highly attractive compared with competitors.
  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.29 for the 2024 fiscal year.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The company has a low valuation given the cash flows generated by its activity.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company sustains low margins.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
DRÄGERWERK AG & CO. KGAA Stock Drägerwerk AG & Co. KGaA
-1.34% 94Cr -
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+2.52% 21TCr
B
DANAHER CORPORATION Stock Danaher Corporation
+6.00% 19TCr
B-
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+29.78% 16TCr
B-
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+2.36% 6.43TCr
A-
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+20.00% 5.57TCr
B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-1.92% 4.84TCr
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-7.58% 3.78TCr
A
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
-0.72% 3.56TCr -
RESMED, INC. Stock ResMed, Inc.
+8.88% 2.81TCr
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. DRW3 Stock
  4. DRW8 Stock
  5. Ratings Drägerwerk AG & Co. KGaA